{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:06:55Z","timestamp":1783181215997,"version":"3.54.6"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2014,10,24]],"date-time":"2014-10-24T00:00:00Z","timestamp":1414108800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0110667","type":"journal-article","created":{"date-parts":[[2014,10,24]],"date-time":"2014-10-24T14:20:00Z","timestamp":1414160400000},"page":"e110667","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":41,"title":["Combined Intravitreal Anti-VEGF and Photodynamic Therapy versus Photodynamic Monotherapy for Polypoidal Choroidal Vasculopathy: A Systematic Review and Meta-Analysis of Comparative Studies"],"prefix":"10.1371","volume":"9","author":[{"given":"Wei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiulan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,10,24]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/IAE.0b013e31826ffe9d","article-title":"Systemic risk factors associated with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration","volume":"33","author":"Y Sakurada","year":"2013","journal-title":"Retina"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.survophthal.2010.03.004","article-title":"Polypoidal choroidal vasculopathy: a review","volume":"55","author":"Y Imamura","year":"2010","journal-title":"Surv Ophthalmol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/ICU.0b013e3282fb7c33","article-title":"Polypoidal choroidal vasculopathy and treatments","volume":"19","author":"F Gomi","year":"2008","journal-title":"Curr Opin Ophthalmol"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Nowak-Sliwinska P, van den Bergh H, Sickenberg M, Koh AH (2013) Photodynamic Therapy for Polypoidal Choroidal Vasculopathy. Prog Retin Eye Res.","DOI":"10.1016\/j.preteyeres.2013.09.003"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/IAE.0b013e31823f9b97","article-title":"Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. 2002","volume":"32","author":"RF Spaide","year":"2012","journal-title":"Retina"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ajo.2011.07.001","article-title":"Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab","volume":"153","author":"K Tomita","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ajo.2013.05.024","article-title":"Comparison of the Effect of Ranibizumab and Verteporfin for Polypoidal Choroidal Vasculopathy: 12-Month LAPTOP Study Results","volume":"156","author":"A Oishi","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/IAE.0b013e3181f274ec","article-title":"Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy","volume":"31","author":"AA Rouvas","year":"2011","journal-title":"Retina"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/eye.2013.179","article-title":"Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy","volume":"27","author":"M Inoue","year":"2013","journal-title":"Eye (Lond)"},{"key":"ref10","first-page":"343","article-title":"Photodynamic Therapy Versus Combination Therapy in Polypoidal Choroidal Vasculopathy: Changes of Aqueous Vascular Endothelial Growth Factor. Am J Ophthalmol","volume":"156","author":"MY Lee","year":"2013"},{"key":"ref11","first-page":"2099","article-title":"Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol","volume":"251","author":"M Saito","year":"2013"},{"key":"ref12","first-page":"832","article-title":"Two-Year Results of Photodynamic Therapy With or Without Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy. J Ocul Pharmacol Ther","volume":"29","author":"Y Sakurada","year":"2013"},{"key":"ref13","first-page":"86","article-title":"Two-Year Outcome after Combination Therapy for Polypoidal Choroidal Vasculopathy: Comparison with Photodynamic Monotherapy and Anti-Vascular Endothelial Growth Factor Monotherapy. Ophthalmologica","volume":"231","author":"HM Kang","year":"2014"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ajo.2012.03.051","article-title":"Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: two years of follow-up","volume":"154","author":"YA Lee","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","article-title":"EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy","volume":"32","author":"A Koh","year":"2012","journal-title":"Retina"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1097\/IAE.0b013e318214d01e","article-title":"Efficacy of combined photodynamic therapy and intravitreal bevacizumab injection versus photodynamic therapy alone in polypoidal choroidal vasculopathy","volume":"31","author":"SJ Kim","year":"2011","journal-title":"Retina"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1097\/IAE.0b013e31820d3f3f","article-title":"Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy","volume":"31","author":"TY Lai","year":"2011","journal-title":"Retina"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ajo.2010.10.030","article-title":"Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy","volume":"151","author":"I Maruko","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ajo.2010.02.008","article-title":"Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy","volume":"150","author":"F Gomi","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"D Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"ref21","unstructured":"Higgins JP, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March, 2011]: The Cochrane Collaboration. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/handbook.cochrane.org\/\" xlink:type=\"simple\">http:\/\/handbook.cochrane.org\/<\/ext-link>"},{"key":"ref22","unstructured":"Wells G, Shea B, O&apos;Connell D, Peterson J, Welch V, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp\" xlink:type=\"simple\">http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp<\/ext-link>"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"JP Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/IAE.0b013e3182852446","article-title":"Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment","volume":"33","author":"AH Koh","year":"2013","journal-title":"Retina"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/ICU.0b013e32835f8eaa","article-title":"Combination therapy for the treatment of neovascular age-related macular degeneration","volume":"24","author":"M Englander","year":"2013","journal-title":"Curr Opin Ophthalmol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ajo.2013.02.006","article-title":"Comparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy","volume":"156","author":"T Sato","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ajo.2012.08.002","article-title":"Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy","volume":"155","author":"CC Gemmy","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000329466","article-title":"One-year results of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy","volume":"226","author":"MH Song","year":"2011","journal-title":"Ophthalmologica"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/bjo.2007.135103","article-title":"Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy","volume":"92","author":"TY Lai","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/bjo.2009.173120","article-title":"Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study","volume":"94","author":"P Ruamviboonsuk","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1097\/IAE.0b013e318236e624","article-title":"Combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy","volume":"32","author":"M Saito","year":"2012","journal-title":"Retina"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/138945011794182782","article-title":"Polypoidal choroidal vasculopathy: recent advances in therapy","volume":"12","author":"G de Crecchio","year":"2011","journal-title":"Curr Drug Targets"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/bjophthalmol-2012-302391","article-title":"A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration","volume":"97","author":"I Krebs","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"ref34","first-page":"2300","article-title":"Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology","volume":"120","author":"L Kodjikian","year":"2013"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"U Chakravarthy","year":"2013","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"DF Martin","year":"2012","journal-title":"Ophthalmology"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0110667","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T17:31:02Z","timestamp":1588959062000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0110667"}},"subtitle":[],"editor":[{"given":"Michael","family":"Hamblin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,10,24]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,10,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0110667","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,24]]}}}